Financhill
Sell
39

ZVRA Quote, Financials, Valuation and Earnings

Last price:
$7.97
Seasonality move :
-13.78%
Day range:
$7.96 - $8.40
52-week range:
$4.20 - $9.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.27x
P/B ratio:
11.34x
Volume:
690.2K
Avg. volume:
410.3K
1-year change:
33.72%
Market cap:
$449.7M
Revenue:
$23.6M
EPS (TTM):
-$2.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ZVRA
Zevra Therapeutics
$8.9M -$0.40 395.13% -53.57% $21.63
GERN
Geron
$45.3M -$0.05 16309.12% -60.37% $4.50
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.16% $1,010.47
SIGA
SIGA Technologies
-- -- -- -- --
TKNO
Alpha Teknova
$8.7M -- 0.73% -- $10.67
VYGR
Voyager Therapeutics
$16.6M -$0.35 -30.56% -119.44% $16.10
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ZVRA
Zevra Therapeutics
$8.31 $21.63 $449.7M -- $0.00 0% 16.27x
GERN
Geron
$1.73 $4.50 $1.1B -- $0.00 0% 14.51x
LLY
Eli Lilly and
$822.51 $1,010.47 $738.8B 70.24x $1.50 0.66% 16.51x
SIGA
SIGA Technologies
$5.76 -- $411.5M 7.02x $0.60 0% 2.98x
TKNO
Alpha Teknova
$5.62 $10.67 $300.3M -- $0.00 0% 6.96x
VYGR
Voyager Therapeutics
$3.89 $16.10 $214.8M 6.11x $0.00 0% 2.80x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ZVRA
Zevra Therapeutics
60% 1.594 13.29% 2.35x
GERN
Geron
29.71% 1.676 5.52% 5.04x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
SIGA
SIGA Technologies
-- 1.118 -- 6.97x
TKNO
Alpha Teknova
14.07% 0.863 3.02% 3.10x
VYGR
Voyager Therapeutics
-- 1.754 -- 5.45x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ZVRA
Zevra Therapeutics
$10.7M -$15.4M -102.42% -208.85% -150.91% -$16.3M
GERN
Geron
$46.8M -$20.1M -45.4% -59.29% -35.02% -$43.8M
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
SIGA
SIGA Technologies
$64M $57.1M 32.37% 32.37% 70.07% $56.3M
TKNO
Alpha Teknova
$2.1M -$5.6M -27.37% -31.69% -60.75% -$1.5M
VYGR
Voyager Therapeutics
-- -$38.3M -21.07% -21.07% -610.05% -$14.7M

Zevra Therapeutics vs. Competitors

  • Which has Higher Returns ZVRA or GERN?

    Geron has a net margin of -296.76% compared to Zevra Therapeutics's net margin of -53.33%. Zevra Therapeutics's return on equity of -208.85% beat Geron's return on equity of -59.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    88.66% -$0.69 $99.2M
    GERN
    Geron
    98.35% -$0.04 $398.8M
  • What do Analysts Say About ZVRA or GERN?

    Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 160.23%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 160.12%. Given that Zevra Therapeutics has higher upside potential than Geron, analysts believe Zevra Therapeutics is more attractive than Geron.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    GERN
    Geron
    4 2 0
  • Is ZVRA or GERN More Risky?

    Zevra Therapeutics has a beta of 1.977, which suggesting that the stock is 97.719% more volatile than S&P 500. In comparison Geron has a beta of 0.535, suggesting its less volatile than the S&P 500 by 46.549%.

  • Which is a Better Dividend Stock ZVRA or GERN?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZVRA or GERN?

    Zevra Therapeutics quarterly revenues are $12M, which are smaller than Geron quarterly revenues of $47.5M. Zevra Therapeutics's net income of -$35.7M is lower than Geron's net income of -$25.4M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 16.27x versus 14.51x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    16.27x -- $12M -$35.7M
    GERN
    Geron
    14.51x -- $47.5M -$25.4M
  • Which has Higher Returns ZVRA or LLY?

    Eli Lilly and has a net margin of -296.76% compared to Zevra Therapeutics's net margin of 32.59%. Zevra Therapeutics's return on equity of -208.85% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    88.66% -$0.69 $99.2M
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About ZVRA or LLY?

    Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 160.23%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.85%. Given that Zevra Therapeutics has higher upside potential than Eli Lilly and, analysts believe Zevra Therapeutics is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    LLY
    Eli Lilly and
    16 4 0
  • Is ZVRA or LLY More Risky?

    Zevra Therapeutics has a beta of 1.977, which suggesting that the stock is 97.719% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock ZVRA or LLY?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZVRA or LLY?

    Zevra Therapeutics quarterly revenues are $12M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Zevra Therapeutics's net income of -$35.7M is lower than Eli Lilly and's net income of $4.4B. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 70.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 16.27x versus 16.51x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    16.27x -- $12M -$35.7M
    LLY
    Eli Lilly and
    16.51x 70.24x $13.5B $4.4B
  • Which has Higher Returns ZVRA or SIGA?

    SIGA Technologies has a net margin of -296.76% compared to Zevra Therapeutics's net margin of 56.17%. Zevra Therapeutics's return on equity of -208.85% beat SIGA Technologies's return on equity of 32.37%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    88.66% -$0.69 $99.2M
    SIGA
    SIGA Technologies
    78.55% $0.63 $215.8M
  • What do Analysts Say About ZVRA or SIGA?

    Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 160.23%. On the other hand SIGA Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Zevra Therapeutics has higher upside potential than SIGA Technologies, analysts believe Zevra Therapeutics is more attractive than SIGA Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    SIGA
    SIGA Technologies
    0 0 0
  • Is ZVRA or SIGA More Risky?

    Zevra Therapeutics has a beta of 1.977, which suggesting that the stock is 97.719% more volatile than S&P 500. In comparison SIGA Technologies has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.414%.

  • Which is a Better Dividend Stock ZVRA or SIGA?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. Zevra Therapeutics pays -- of its earnings as a dividend. SIGA Technologies pays out 72.05% of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZVRA or SIGA?

    Zevra Therapeutics quarterly revenues are $12M, which are smaller than SIGA Technologies quarterly revenues of $81.5M. Zevra Therapeutics's net income of -$35.7M is lower than SIGA Technologies's net income of $45.8M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while SIGA Technologies's PE ratio is 7.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 16.27x versus 2.98x for SIGA Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    16.27x -- $12M -$35.7M
    SIGA
    SIGA Technologies
    2.98x 7.02x $81.5M $45.8M
  • Which has Higher Returns ZVRA or TKNO?

    Alpha Teknova has a net margin of -296.76% compared to Zevra Therapeutics's net margin of -61.73%. Zevra Therapeutics's return on equity of -208.85% beat Alpha Teknova's return on equity of -31.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    88.66% -$0.69 $99.2M
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
  • What do Analysts Say About ZVRA or TKNO?

    Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 160.23%. On the other hand Alpha Teknova has an analysts' consensus of $10.67 which suggests that it could grow by 95.73%. Given that Zevra Therapeutics has higher upside potential than Alpha Teknova, analysts believe Zevra Therapeutics is more attractive than Alpha Teknova.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    TKNO
    Alpha Teknova
    4 2 0
  • Is ZVRA or TKNO More Risky?

    Zevra Therapeutics has a beta of 1.977, which suggesting that the stock is 97.719% more volatile than S&P 500. In comparison Alpha Teknova has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ZVRA or TKNO?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alpha Teknova offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Alpha Teknova pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZVRA or TKNO?

    Zevra Therapeutics quarterly revenues are $12M, which are larger than Alpha Teknova quarterly revenues of $9.3M. Zevra Therapeutics's net income of -$35.7M is lower than Alpha Teknova's net income of -$5.7M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Alpha Teknova's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 16.27x versus 6.96x for Alpha Teknova. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    16.27x -- $12M -$35.7M
    TKNO
    Alpha Teknova
    6.96x -- $9.3M -$5.7M
  • Which has Higher Returns ZVRA or VYGR?

    Voyager Therapeutics has a net margin of -296.76% compared to Zevra Therapeutics's net margin of -549.33%. Zevra Therapeutics's return on equity of -208.85% beat Voyager Therapeutics's return on equity of -21.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    88.66% -$0.69 $99.2M
    VYGR
    Voyager Therapeutics
    -- -$0.59 $299.8M
  • What do Analysts Say About ZVRA or VYGR?

    Zevra Therapeutics has a consensus price target of $21.63, signalling upside risk potential of 160.23%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 313.88%. Given that Voyager Therapeutics has higher upside potential than Zevra Therapeutics, analysts believe Voyager Therapeutics is more attractive than Zevra Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    VYGR
    Voyager Therapeutics
    11 0 0
  • Is ZVRA or VYGR More Risky?

    Zevra Therapeutics has a beta of 1.977, which suggesting that the stock is 97.719% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.87699999999999%.

  • Which is a Better Dividend Stock ZVRA or VYGR?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZVRA or VYGR?

    Zevra Therapeutics quarterly revenues are $12M, which are larger than Voyager Therapeutics quarterly revenues of $6.3M. Zevra Therapeutics's net income of -$35.7M is lower than Voyager Therapeutics's net income of -$34.5M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 16.27x versus 2.80x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    16.27x -- $12M -$35.7M
    VYGR
    Voyager Therapeutics
    2.80x 6.11x $6.3M -$34.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Pepsi Vs Coke Stock: Which Is Best?
Pepsi Vs Coke Stock: Which Is Best?

Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
52
RGC alert for Mar 19

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Sell
46
CVNA alert for Mar 19

Carvana [CVNA] is down 10.69% over the past day.

Buy
93
ESLT alert for Mar 19

Elbit Systems [ESLT] is up 10.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock